Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
How the UK’s rollback of banking regulations could risk another financial crisis 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
China's Refining Industry Faces Major Shakeup Amid Challenges 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
U.S. Stock Futures Rise as Trump Takes Office, Corporate Earnings Awaited 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
S&P 500 Surges Ahead of Trump Inauguration as Markets Rally 
Gold Prices Rise as Markets Await Trump’s Policy Announcements 
Mexico's Undervalued Equity Market Offers Long-Term Investment Potential 
Elliott Investment Management Takes Significant Stake in BP to Push for Value Growth 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
U.S. Condemns China's Dominance in Global Shipbuilding and Maritime Sectors 
Samsung Biologics would invest 1.74 trillion in building a massive fourth plant in Songdo, Incheon, that would employ 1,800 new employees by 2023 and produce 256,000 liters of drug substances in a single generation.
According to CEO Kim Tae-han, the construction will increase its output at its Songdo complex 1 to 620,000 liters, accounting for 30 percent of the world’s contract manufacturing market.
Samsung Biologics currently has a combined 364,000-liter capacity at its three existing plants, with one of those producing 180,000 liters and touted as having the world’s largest single-plant capacity.
Construction of the fourth plant will take 36 months and poised to create 27,000 jobs and bring in 5.6 trillion won in economic benefits.
Plant 4 will be a hybrid that has both stainless steel and single-use disposable bioreactors.
With speed being of critical significance in the biologics market, the new plant will be a game-changer.
It would provide a one-stop service comprising of cell line development and the manufacturing of clinical samples, active pharmaceutical ingredients, drug substances, and fill-and-finish drug products.
The one-stop service would dramatically reduce the time spent on commercializing a drug.
